1
|
Wang L, Hubert F, Idres S, Belacel-Ouari M, Domergue V, Domenichini S, Lefebvre F, Mika D, Fischmeister R, Leblais V, Manoury B. Phosphodiesterases type 2, 3 and 4 promote vascular tone in mesenteric arteries from rats with heart failure. Eur J Pharmacol 2023; 944:175562. [PMID: 36736940 DOI: 10.1016/j.ejphar.2023.175562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 01/09/2023] [Accepted: 01/30/2023] [Indexed: 02/04/2023]
Abstract
Phosphodiesterases (PDE) type 3 and 4 promote vasoconstriction by hydrolysing cAMP. In experimental heart failure (HF), PDE3 makes PDE4 redundant in aorta, but it is not known if this occurs in resistance vessels, such as mesenteric artery. As PDE2 is increased in the failing myocardium, its possible role in the vasculature also needs to be addressed. Here, the function of PDE2, PDE3 and PDE4 in rat mesenteric arteries was characterized in experimental HF. Mesenteric arteries were isolated from rats sacrificed 22 weeks after surgical stenosis of the ascending aorta (HF), or Sham surgery. PDE inhibitors were used to probe isoenzyme contributions in enzymatic and isometric tension assays. PDE2 and PDE4 activities, but not PDE3 activity, facilitate contraction produced by the thromboxane analogue U46619 in Sham arteries, while in HF all three isoenzymes contribute to this response. NO synthase inhibition by L-NAME abolished the action of the PDE2 inhibitor. L-NAME eliminated the contribution of PDE4 in HF, but unmasked a contribution for PDE3 in Sham. PDE3 and PDE4 activities attenuated relaxant response to β-adrenergic stimulation in Sham and HF. PDE2 did not participate in cAMP or cGMP-mediated relaxant responses. PDE3 and PDE4 cAMP-hydrolysing activities were smaller in HF mesenteric arteries, while PDE2 activity was scarce in both groups. Endothelial cells and arterial myocytes displayed PDE2 immunolabelling. We highlight that, by contrast with previous observations in aorta, PDE4 participates equally as PDE3 in contracting mesenteric artery in HF. PDE2 activity emerges as a promoter of contractile response that is preserved in HF.
Collapse
Affiliation(s)
- Liting Wang
- Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France
| | - Fabien Hubert
- Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France
| | - Sarah Idres
- Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France
| | | | - Valérie Domergue
- Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, Orsay, France
| | - Séverine Domenichini
- Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, Orsay, France
| | | | - Delphine Mika
- Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France
| | | | | | - Boris Manoury
- Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France.
| |
Collapse
|
2
|
Subramaniam G, Schleicher K, Kovanich D, Zerio A, Folkmanaite M, Chao YC, Surdo NC, Koschinski A, Hu J, Scholten A, Heck AJ, Ercu M, Sholokh A, Park KC, Klussmann E, Meraviglia V, Bellin M, Zanivan S, Hester S, Mohammed S, Zaccolo M. Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy. Circ Res 2023; 132:828-848. [PMID: 36883446 PMCID: PMC10045983 DOI: 10.1161/circresaha.122.321448] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 02/28/2023] [Accepted: 03/01/2023] [Indexed: 03/09/2023]
Abstract
BACKGROUND Signaling by cAMP is organized in multiple distinct subcellular nanodomains regulated by cAMP-hydrolyzing PDEs (phosphodiesterases). Cardiac β-adrenergic signaling has served as the prototypical system to elucidate cAMP compartmentalization. Although studies in cardiac myocytes have provided an understanding of the location and properties of a handful of cAMP subcellular compartments, an overall view of the cellular landscape of cAMP nanodomains is missing. METHODS Here, we combined an integrated phosphoproteomics approach that takes advantage of the unique role that individual PDEs play in the control of local cAMP, with network analysis to identify previously unrecognized cAMP nanodomains associated with β-adrenergic stimulation. We then validated the composition and function of one of these nanodomains using biochemical, pharmacological, and genetic approaches and cardiac myocytes from both rodents and humans. RESULTS We demonstrate the validity of the integrated phosphoproteomic strategy to pinpoint the location and provide critical cues to determine the function of previously unknown cAMP nanodomains. We characterize in detail one such compartment and demonstrate that the PDE3A2 isoform operates in a nuclear nanodomain that involves SMAD4 (SMAD family member 4) and HDAC-1 (histone deacetylase 1). Inhibition of PDE3 results in increased HDAC-1 phosphorylation, leading to inhibition of its deacetylase activity, derepression of gene transcription, and cardiac myocyte hypertrophic growth. CONCLUSIONS We developed a strategy for detailed mapping of subcellular PDE-specific cAMP nanodomains. Our findings reveal a mechanism that explains the negative long-term clinical outcome observed in patients with heart failure treated with PDE3 inhibitors.
Collapse
Affiliation(s)
- Gunasekaran Subramaniam
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Katharina Schleicher
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Duangnapa Kovanich
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
- Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, the Netherlands (D.K., A.S., A.J.R.H.)
- Centre for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Thailand (D.K.)
| | - Anna Zerio
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Milda Folkmanaite
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Ying-Chi Chao
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Nicoletta C. Surdo
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
- Now with Neuroscience Institute, National Research Council of Italy (CNR), Padova (N.C.S.)
| | - Andreas Koschinski
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Jianshu Hu
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Arjen Scholten
- Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, the Netherlands (D.K., A.S., A.J.R.H.)
| | - Albert J.R. Heck
- Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, the Netherlands (D.K., A.S., A.J.R.H.)
| | - Maria Ercu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and German Centre for Cardiovascular Research, Partner Site Berlin (M.E., A.S., E.K.)
| | - Anastasiia Sholokh
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and German Centre for Cardiovascular Research, Partner Site Berlin (M.E., A.S., E.K.)
| | - Kyung Chan Park
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
| | - Enno Klussmann
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and German Centre for Cardiovascular Research, Partner Site Berlin (M.E., A.S., E.K.)
| | - Viviana Meraviglia
- Department of Anatomy and Embryology, Leiden University Medical Center, the Netherlands (V.M., M.B.)
| | - Milena Bellin
- Department of Anatomy and Embryology, Leiden University Medical Center, the Netherlands (V.M., M.B.)
- Department of Biology, University of Padua, Italy (M.B.)
- Veneto Institute of Molecular Medicine, Padua, Italy (M.B.)
| | - Sara Zanivan
- Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.)
- Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.)
| | - Svenja Hester
- Department of Biochemistry (S.H., S.M.), University of Oxford, United Kingdom
| | - Shabaz Mohammed
- Department of Biochemistry (S.H., S.M.), University of Oxford, United Kingdom
| | - Manuela Zaccolo
- Department of Physiology, Anatomy and Genetics (G.S., K.S., D.K., A.Z., M.F., Y.-C.C., N.C.S., A.K., J.H., K.C.P., M.Z.), University of Oxford, United Kingdom
- Oxford NIHR Biomedical Research Centre (M.Z.)
| |
Collapse
|
3
|
Ercu M, Mücke MB, Pallien T, Markó L, Sholokh A, Schächterle C, Aydin A, Kidd A, Walter S, Esmati Y, McMurray BJ, Lato DF, Yumi Sunaga-Franze D, Dierks PH, Flores BIM, Walker-Gray R, Gong M, Merticariu C, Zühlke K, Russwurm M, Liu T, Batolomaeus TUP, Pautz S, Schelenz S, Taube M, Napieczynska H, Heuser A, Eichhorst J, Lehmann M, Miller DC, Diecke S, Qadri F, Popova E, Langanki R, Movsesian MA, Herberg FW, Forslund SK, Müller DN, Borodina T, Maass PG, Bähring S, Hübner N, Bader M, Klussmann E. Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage. Circulation 2022; 146:1758-1778. [PMID: 36259389 DOI: 10.1161/circulationaha.122.060210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 08/24/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND Phosphodiesterase 3A (PDE3A) gain-of-function mutations cause hypertension with brachydactyly (HTNB) and lead to stroke. Increased peripheral vascular resistance, rather than salt retention, is responsible. It is surprising that the few patients with HTNB examined so far did not develop cardiac hypertrophy or heart failure. We hypothesized that, in the heart, PDE3A mutations could be protective. METHODS We studied new patients. CRISPR-Cas9-engineered rat HTNB models were phenotyped by telemetric blood pressure measurements, echocardiography, microcomputed tomography, RNA-sequencing, and single nuclei RNA-sequencing. Human induced pluripotent stem cells carrying PDE3A mutations were established, differentiated to cardiomyocytes, and analyzed by Ca2+ imaging. We used Förster resonance energy transfer and biochemical assays. RESULTS We identified a new PDE3A mutation in a family with HTNB. It maps to exon 13 encoding the enzyme's catalytic domain. All hitherto identified HTNB PDE3A mutations cluster in exon 4 encoding a region N-terminally from the catalytic domain of the enzyme. The mutations were recapitulated in rat models. Both exon 4 and 13 mutations led to aberrant phosphorylation, hyperactivity, and increased PDE3A enzyme self-assembly. The left ventricles of our patients with HTNB and the rat models were normal despite preexisting hypertension. A catecholamine challenge elicited cardiac hypertrophy in HTNB rats only to the level of wild-type rats and improved the contractility of the mutant hearts, compared with wild-type rats. The β-adrenergic system, phosphodiesterase activity, and cAMP levels in the mutant hearts resembled wild-type hearts, whereas phospholamban phosphorylation was decreased in the mutants. In our induced pluripotent stem cell cardiomyocyte models, the PDE3A mutations caused adaptive changes of Ca2+ cycling. RNA-sequencing and single nuclei RNA-sequencing identified differences in mRNA expression between wild-type and mutants, affecting, among others, metabolism and protein folding. CONCLUSIONS Although in vascular smooth muscle, PDE3A mutations cause hypertension, they confer protection against hypertension-induced cardiac damage in hearts. Nonselective PDE3A inhibition is a final, short-term option in heart failure treatment to increase cardiac cAMP and improve contractility. Our data argue that mimicking the effect of PDE3A mutations in the heart rather than nonselective PDE3 inhibition is cardioprotective in the long term. Our findings could facilitate the search for new treatments to prevent hypertension-induced cardiac damage.
Collapse
Affiliation(s)
- Maria Ercu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| | - Michael B Mücke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
| | - Tamara Pallien
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| | - Lajos Markó
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Anastasiia Sholokh
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
| | - Carolin Schächterle
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Atakan Aydin
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Alexa Kidd
- Clinical Genetics Ltd, Christchurch, New Zealand (A.K.)
| | | | - Yasmin Esmati
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Brandon J McMurray
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada (B.J.M., D.F.L., P.G.M.)
| | - Daniella F Lato
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada (B.J.M., D.F.L., P.G.M.)
| | - Daniele Yumi Sunaga-Franze
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Philip H Dierks
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Barbara Isabel Montesinos Flores
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Ryan Walker-Gray
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Maolian Gong
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Claudia Merticariu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Kerstin Zühlke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Michael Russwurm
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät MA N1, Ruhr-Universität Bochum, Germany (M.R.)
| | - Tiannan Liu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Theda U P Batolomaeus
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Sabine Pautz
- Department of Biochemistry, University of Kassel, Germany (S.P., F.W.H.)
| | - Stefanie Schelenz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Martin Taube
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Hanna Napieczynska
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Jenny Eichhorst
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L.)
| | - Martin Lehmann
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L.)
| | - Duncan C Miller
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| | - Sebastian Diecke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Berlin Institute of Health (BIH), Germany (S.D., S.K.F.)
| | - Fatimunnisa Qadri
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Elena Popova
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Reika Langanki
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | | | | | - Sofia K Forslund
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
- Berlin Institute of Health (BIH), Germany (S.D., S.K.F.)
- European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany (S.K.F.)
| | - Dominik N Müller
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Tatiana Borodina
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Philipp G Maass
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada (B.J.M., D.F.L., P.G.M.)
- Department of Molecular Genetics, University of Toronto, ON, Canada (P.G.M.)
| | - Sylvia Bähring
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Norbert Hübner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Institute for Biology, University of Lübeck, Germany (M.B.)
| | - Enno Klussmann
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| |
Collapse
|
4
|
Nitration of protein kinase G-Iα modulates cyclic nucleotide crosstalk via phosphodiesterase 3A: Implications for acute lung injury. J Biol Chem 2021; 297:100946. [PMID: 34252457 PMCID: PMC8342797 DOI: 10.1016/j.jbc.2021.100946] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 06/22/2021] [Accepted: 07/08/2021] [Indexed: 12/05/2022] Open
Abstract
Phosphodiesterase 3A (PDE3A) selectively cleaves the phosphodiester bond of cAMP and is inhibited by cGMP, making it an important regulator of cAMP–cGMP signaling crosstalk in the pulmonary vasculature. In addition, the nitric oxide–cGMP axis is known to play an important role in maintaining endothelial barrier function. However, the potential role of protein kinase G-Iα (PKG-Iα) in this protective process is unresolved and was the focus of our study. We describe here a novel mechanism regulating PDE3A activity, which involves a PKG-Iα–dependent inhibitory phosphorylation of PDE3A at serine 654. We also show that this phosphorylation is critical for maintaining intracellular cAMP levels in the pulmonary endothelium and endothelial barrier integrity. In an animal model of acute lung injury (ALI) induced by challenging mice with lipopolysaccharide (LPS), an increase in PDE3 activity and a decrease in cAMP levels in lung tissue was associated with reduced PKG activity upon PKG-Iα nitration at tyrosine 247. The peroxynitrite scavenger manganese (III) tetrakis(1-methyl-4-pyridyl)porphyrin prevented this increase in PDE3 activity in LPS-exposed lungs. In addition, site-directed mutagenesis of PDE3A to replace serine 654 with alanine yielded a mutant protein that was insensitive to PKG-dependent regulation. Taken together, our data demonstrate a novel functional link between nitrosative stress induced by LPS during ALI and the downregulation of barrier-protective intracellular cAMP levels. Our data also provide new evidence that PKG-Iα is critical for endothelial barrier maintenance and that preservation of its catalytic activity may be efficacious in ALI therapy.
Collapse
|
5
|
The PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related Multigene Family. Trends Genet 2021; 37:669-681. [PMID: 33832760 DOI: 10.1016/j.tig.2021.03.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 03/07/2021] [Accepted: 03/09/2021] [Indexed: 12/30/2022]
Abstract
The phosphodiesterase (PDE)-opathies, an expanding set of disorders caused by germline mutations in cyclic nucleotide PDEs, present an intriguing paradox. The enzymes encoded by the PDE family all hydrolyze cAMP and/or cGMP, but mutations in different family members produce very divergent phenotypes. Three interacting factors have been shown recently to contribute to this phenotypic diversity: (i) the 21 genes encode over 80 different isoforms, using alternative mRNA splicing and related mechanisms; (ii) the various isoforms have different regulatory mechanisms, mediated by their unique amino-terminal regulatory domains; (iii) the isoforms differ widely in their pattern of tissue expression. These mechanisms explain why many PDE-opathies are gain-of-function mutations and how they exemplify uniqueness and redundancy within a multigene family.
Collapse
|
6
|
Wu X, Schnitzler GR, Gao GF, Diamond B, Baker AR, Kaplan B, Williamson K, Westlake L, Lorrey S, Lewis TA, Garvie CW, Lange M, Hayat S, Seidel H, Doench J, Cherniack AD, Kopitz C, Meyerson M, Greulich H. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem 2020; 295:3431-3446. [PMID: 32005668 DOI: 10.1074/jbc.ra119.011191] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 01/27/2020] [Indexed: 01/08/2023] Open
Abstract
Cytotoxic molecules can kill cancer cells by disrupting critical cellular processes or by inducing novel activities. 6-(4-(Diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (DNMDP) is a small molecule that kills cancer cells by generation of novel activity. DNMDP induces complex formation between phosphodiesterase 3A (PDE3A) and schlafen family member 12 (SLFN12) and specifically kills cancer cells expressing elevated levels of these two proteins. Here, we examined the characteristics and covariates of the cancer cell response to DNMDP. On average, the sensitivity of human cancer cell lines to DNMDP is correlated with PDE3A expression levels. However, DNMDP could also bind the related protein, PDE3B, and PDE3B supported DNMDP sensitivity in the absence of PDE3A expression. Although inhibition of PDE3A catalytic activity did not account for DNMDP sensitivity, we found that expression of the catalytic domain of PDE3A in cancer cells lacking PDE3A is sufficient to confer sensitivity to DNMDP, and substitutions in the PDE3A active site abolish compound binding. Moreover, a genome-wide CRISPR screen identified the aryl hydrocarbon receptor-interacting protein (AIP), a co-chaperone protein, as required for response to DNMDP. We determined that AIP is also required for PDE3A-SLFN12 complex formation. Our results provide mechanistic insights into how DNMDP induces PDE3A-SLFN12 complex formation, thereby killing cancer cells with high levels of PDE3A and SLFN12 expression.
Collapse
Affiliation(s)
- Xiaoyun Wu
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142
| | | | - Galen F Gao
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142
| | - Brett Diamond
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142
| | - Andrew R Baker
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142
| | - Bethany Kaplan
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142
| | | | | | - Selena Lorrey
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142
| | - Timothy A Lewis
- Center for the Development of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142
| | - Colin W Garvie
- Center for the Development of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142
| | - Martin Lange
- Research and Development, Pharmaceuticals, Bayer AG, 13342 Berlin, Germany
| | - Sikander Hayat
- Research and Development, Pharmaceuticals, Bayer AG, 13342 Berlin, Germany
| | - Henrik Seidel
- Research and Development, Pharmaceuticals, Bayer AG, 13342 Berlin, Germany
| | - John Doench
- Genetic Perturbation Platform, Broad Institute, Cambridge, Massachusetts 02142
| | - Andrew D Cherniack
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215
| | - Charlotte Kopitz
- Research and Development, Pharmaceuticals, Bayer AG, 13342 Berlin, Germany
| | - Matthew Meyerson
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215
| | - Heidi Greulich
- Cancer Program, Broad Institute, Cambridge, Massachusetts 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215.
| |
Collapse
|
7
|
Li D, Chen J, Ai Y, Gu X, Li L, Che D, Jiang Z, Li L, Chen S, Huang H, Wang J, Cai T, Cao Y, Qi X, Wang X. Estrogen-Related Hormones Induce Apoptosis by Stabilizing Schlafen-12 Protein Turnover. Mol Cell 2019; 75:1103-1116.e9. [PMID: 31420216 DOI: 10.1016/j.molcel.2019.06.040] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 05/29/2019] [Accepted: 06/25/2019] [Indexed: 12/31/2022]
Abstract
The mitochondrial pathway of apoptosis is controlled by the ratio of anti- and pro-apoptotic members of the Bcl-2 family of proteins. The molecular events underlying how a given physiological stimulus changes this ratio to trigger apoptosis remains unclear. We report here that human 17-β-estradiol (E2) and its related steroid hormones induce apoptosis by binding directly to phosphodiesterase 3A, which in turn recruits and stabilizes an otherwise fast-turnover protein Schlafen 12 (SLFN12). The elevated SLFN12 binds to ribosomes to exclude the recruitment of signal recognition particles (SRPs), thereby blocking the continuous protein translation occurring on the endoplasmic reticulum of E2-treated cells. These proteins include Bcl-2 and Mcl-1, whose ensuing decrease triggers apoptosis. The SLFN12 protein and an apoptosis activation marker were co-localized in syncytiotrophoblast of human placentas, where levels of estrogen-related hormones are high, and dynamic cell turnover by apoptosis is critical for successful implantation and placenta development.
Collapse
Affiliation(s)
- Dianrong Li
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Jie Chen
- College of Biological Sciences, China Agricultural University, Beijing 100083, China; National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China
| | - Youwei Ai
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Xiaoqiong Gu
- Department of Blood Transfusion, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China; Clinical Biological Resource Bank and Clinical Lab, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
| | - Li Li
- Department of Gynecology and Obstetrics, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
| | - Di Che
- Clinical Biological Resource Bank and Clinical Lab, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
| | - Zhaodi Jiang
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Lin Li
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - She Chen
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Huangwei Huang
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Jiawen Wang
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Tao Cai
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Yang Cao
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Xiangbin Qi
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
| | - Xiaodong Wang
- National Institute of Biological Sciences, 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China.
| |
Collapse
|
8
|
Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, Gagnon DR, DuVall SL, Li J, Peloso GM, Chaffin M, Small AM, Huang J, Tang H, Lynch JA, Ho YL, Liu DJ, Emdin CA, Li AH, Huffman JE, Lee JS, Natarajan P, Chowdhury R, Saleheen D, Vujkovic M, Baras A, Pyarajan S, Di Angelantonio E, Neale BM, Naheed A, Khera AV, Danesh J, Chang KM, Abecasis G, Willer C, Dewey FE, Carey DJ, Concato J, Gaziano JM, O'Donnell CJ, Tsao PS, Kathiresan S, Rader DJ, Wilson PWF, Assimes TL. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet 2018; 50:1514-1523. [PMID: 30275531 PMCID: PMC6521726 DOI: 10.1038/s41588-018-0222-9] [Citation(s) in RCA: 395] [Impact Index Per Article: 65.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 08/03/2018] [Indexed: 01/17/2023]
Abstract
The Million Veteran Program (MVP) was established in 2011 as a national
research initiative to determine how genetic variation influences the health of
U.S. military veterans. We genotyped 312,571 MVP participants using a custom
biobank array and linked the genetic data to laboratory and clinical phenotypes
extracted from electronic health records covering a median of 10.0 years of
follow-up. Among 297,626 veterans with at least 1 blood lipid measurement
including 57,332 blacks and 24,743 Hispanics, we tested up to ~32 million
variants for association with lipid levels and identified 118 novel genome-wide
significant loci after meta-analysis with data from the Global Lipids Genetics
Consortium (total N > 600,000). Through a focus on mutations predicted to
result in a loss of gene function and a phenome-wide association study, we
propose novel indications for pharmaceutical inhibitors targeting PCSK9
(abdominal aortic aneurysm), ANGPTL4 (type 2 diabetes), and PDE3B (triglycerides
and coronary disease).
Collapse
Affiliation(s)
- Derek Klarin
- Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Boston VA Healthcare System, Boston, MA, USA
| | - Scott M Damrauer
- Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.,Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Kelly Cho
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
| | - Yan V Sun
- Department of Epidemiology, Rollins School of Public Health, Department of Biomedical Informatics, School of Medicine, Emory University, Atlanta, GA, USA
| | | | - Jacqueline Honerlaw
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
| | - David R Gagnon
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.,Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - Scott L DuVall
- VA Salt Lake City Health Care System, Salt Lake City, UT, USA.,Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Jin Li
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.,VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Gina M Peloso
- Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - Mark Chaffin
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Aeron M Small
- Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.,Department of Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Jie Huang
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
| | - Hua Tang
- Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
| | - Julie A Lynch
- VA Salt Lake City Health Care System, Salt Lake City, UT, USA.,University of Massachusetts College of Nursing and Health Sciences, Boston, MA, USA
| | - Yuk-Lam Ho
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
| | - Dajiang J Liu
- Department of Public Health Sciences, Institute of Personalized Medicine, Penn State College of Medicine, Hershey, PA, USA
| | - Connor A Emdin
- Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | - Jennifer E Huffman
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
| | - Jennifer S Lee
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.,VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Pradeep Natarajan
- Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Rajiv Chowdhury
- Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Danish Saleheen
- Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.,Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Marijana Vujkovic
- Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.,Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Aris Baras
- Regeneron Genetics Center, Tarrytown, NY, USA
| | - Saiju Pyarajan
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.,Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Emanuele Di Angelantonio
- Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Benjamin M Neale
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.,Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Aliya Naheed
- Initiative for Noncommunicable Diseases, Health Systems and Population Studies Division, International Centre for Diarrheal Disease Research, Dhaka, Bangladesh
| | - Amit V Khera
- Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - John Danesh
- Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Kyong-Mi Chang
- Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.,Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Gonçalo Abecasis
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Cristen Willer
- Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.,Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.,Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA
| | | | | | | | | | | | | | - John Concato
- Department of Medicine, Yale School of Medicine, New Haven, CT, USA.,Clinical Epidemiology Research Center, VA Connecticut Healthcare System, West Haven, CT, USA
| | - J Michael Gaziano
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.,Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.,Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Christopher J O'Donnell
- Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.,Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Philip S Tsao
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.,VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Sekar Kathiresan
- Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Daniel J Rader
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.,Department of Medicine, Harvard Medical School, Boston, MA, USA.,Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.,Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.,Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Peter W F Wilson
- Atlanta VA Medical Center, Decatur, GA, USA.,Emory Clinical Cardiovascular Research Institute, Atlanta, GA, USA
| | - Themistocles L Assimes
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. .,VA Palo Alto Health Care System, Palo Alto, CA, USA.
| |
Collapse
|
9
|
Movsesian M, Ahmad F, Hirsch E. Functions of PDE3 Isoforms in Cardiac Muscle. J Cardiovasc Dev Dis 2018; 5:jcdd5010010. [PMID: 29415428 PMCID: PMC5872358 DOI: 10.3390/jcdd5010010] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 01/30/2018] [Accepted: 02/01/2018] [Indexed: 12/21/2022] Open
Abstract
Isoforms in the PDE3 family of cyclic nucleotide phosphodiesterases have important roles in cyclic nucleotide-mediated signalling in cardiac myocytes. These enzymes are targeted by inhibitors used to increase contractility in patients with heart failure, with a combination of beneficial and adverse effects on clinical outcomes. This review covers relevant aspects of the molecular biology of the isoforms that have been identified in cardiac myocytes; the roles of these enzymes in modulating cAMP-mediated signalling and the processes mediated thereby; and the potential for targeting these enzymes to improve the profile of clinical responses.
Collapse
Affiliation(s)
- Matthew Movsesian
- Department of Internal Medicine/Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT 841132, USA.
| | - Faiyaz Ahmad
- Vascular Biology and Hypertension Branch, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA.
| | - Emilio Hirsch
- Department of Molecular Biotechnology and Health Sciences, Center for Molecular Biotechnology, University of Turin, 10126 Turin, Italy.
| |
Collapse
|
10
|
Sala V, Margaria JP, Murabito A, Morello F, Ghigo A, Hirsch E. Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). Curr Heart Fail Rep 2017; 14:187-196. [PMID: 28451983 DOI: 10.1007/s11897-017-0331-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
PURPOSE OF REVIEW Heart Failure with preserved Ejection Fraction (HFpEF) is a prevalent disease with considerable individual and societal burden. HFpEF patients often suffer from multiple pathological conditions thatcomplicate management and adversely affect outcome, including pulmonary hypertension and chronic obstructive pulmonary disease (COPD). To date, no treatment proved to be fully effective in reducing morbidity and mortality in HFpEF, possibly due to an incomplete understanding of the underlying molecular mechanisms. RECENT FINDINGS The emerging view proposes chronic systemic inflammation, leading to endothelial dysfunction and interstitial fibrosis, as a prominent cause of HFpEF, rather than a mere co-existent disease. In the last decade, efforts from pharmaceutical companies attempted to target pharmacologically enzymes which play key roles in systemic and lung inflammation, such as the cyclic nucleotide-degrading enzymes phosphodiesterases (PDEs) and phosphoinositide-3 phosphate kinases (PI3Ks), especially to limit COPD. In this review, we will summarize major successes and drawbacks of hitting these enzymes to tackle inflammation in HFpEF-associated co-morbidities, with a major focus on the results of completed and ongoing clinical trials. Finally, we will discuss the potential of repurposing and/or developing new PDE and PI3K inhibitors for HFpEF therapy.
Collapse
Affiliation(s)
- Valentina Sala
- Department of Molecular Biotechnology, Molecular Biotechnology Center, University of Torino, Torino, Italy
- S.C. Medicina d'Urgenza, A.O.U. Città della Salute e della Scienza, Molinette Hospital, Torino, Italy
| | - Jean Piero Margaria
- Department of Molecular Biotechnology, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Alessandra Murabito
- Department of Molecular Biotechnology, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Fulvio Morello
- S.C. Medicina d'Urgenza, A.O.U. Città della Salute e della Scienza, Molinette Hospital, Torino, Italy
| | - Alessandra Ghigo
- Department of Molecular Biotechnology, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Emilio Hirsch
- Department of Molecular Biotechnology, Molecular Biotechnology Center, University of Torino, Torino, Italy.
| |
Collapse
|
11
|
Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease. Handb Exp Pharmacol 2017; 243:249-269. [PMID: 27787716 DOI: 10.1007/164_2016_82] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
An important hallmark of cardiac failure is abnormal second messenger signaling due to impaired synthesis and catabolism of cyclic adenosine 3',5'- monophosphate (cAMP) and cyclic guanosine 3',5'- monophosphate (cGMP). Their dysregulation, altered intracellular targeting, and blunted responsiveness to stimulating pathways all contribute to pathological remodeling, muscle dysfunction, reduced cell survival and metabolism, and other abnormalities. Therapeutic enhancement of either cyclic nucleotides can be achieved by stimulating their synthesis and/or by suppressing members of the family of cyclic nucleotide phosphodiesterases (PDEs). The heart expresses seven of the eleven major PDE subtypes - PDE1, 2, 3, 4, 5, 8, and 9. Their differential control over cAMP and cGMP signaling in various cell types, including cardiomyocytes, provides intriguing therapeutic opportunities to counter heart disease. This review examines the roles of these PDEs in the failing and hypertrophied heart and summarizes experimental and clinical data that have explored the utility of targeted PDE inhibition.
Collapse
|
12
|
SFPQ, a multifunctional nuclear protein, regulates the transcription of PDE3A. Biosci Rep 2017; 37:BSR20170975. [PMID: 28743736 PMCID: PMC5548871 DOI: 10.1042/bsr20170975] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 07/22/2017] [Accepted: 07/25/2017] [Indexed: 11/30/2022] Open
Abstract
Phosphodiesterase 3A (PDE3A), a member of the cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE) family, plays important roles in oocyte maturation and vascular smooth muscle cell proliferation. However, the molecular mechanisms that regulate PDE3A gene expression remain largely unknown. In the present study, we investigated the transcriptional regulation of PDE3A, and found that the splicing factor proline- and glutamine-rich (SFPQ) protein modulated PDE3A mRNA levels. Multiple transcription start sites (TSS1, 2, and 3) were identified within the first exon of PDE3A using 5′-rapid amplification of cDNA ends (RACE). Variable expression levels of three PDE3A variants were also observed in human tissues and HeLa cells. Several putative SFPQ-binding sites were identified upstream of the regulatory region of PDE3A-TSSs using ChIP sequencing (ChIP-seq). Serum-induced PDE3A expression was affected by increasing the amount of SFPQ binding to the upstream regulatory region of PDE3A. In addition, transcription of PDE3A was lower in human cervical adenocarcinoma cells compared with normal cervical tissue. Furthermore, overexpression of PDE3A induced sensitivity to anticancer therapeutic agent, 6-(4-(diethylamino)-3-nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (DNMDP), in HeLa cells. Taken together, these results suggest that SFPQ functions as a transcriptional activator of PDE3A, which is involved in the regulation of DNMDP sensitivity, offering a novel molecular target for the development of anticancer therapies.
Collapse
|
13
|
Kokkonen K, Kass DA. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. Annu Rev Pharmacol Toxicol 2016; 57:455-479. [PMID: 27732797 DOI: 10.1146/annurev-pharmtox-010716-104756] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cyclic nucleotide phosphodiesterases (PDEs) form an 11-member superfamily comprising 100 different isoforms that regulate the second messengers cyclic adenosine or guanosine 3',5'-monophosphate (cAMP or cGMP). These PDE isoforms differ with respect to substrate selectivity and their localized control of cAMP and cGMP within nanodomains that target specific cellular pools and synthesis pathways for the cyclic nucleotides. Seven PDE family members are physiologically relevant to regulating cardiac function, disease remodeling of the heart, or both: PDE1 and PDE2, both dual-substrate (cAMP and cGMP) esterases; PDE3, PDE4, and PDE8, which principally hydrolyze cAMP; and PDE5A and PDE9A, which target cGMP. New insights regarding the different roles of PDEs in health and disease and their local signaling control are broadening the potential therapeutic utility for PDE-selective inhibitors. In this review, we discuss these PDEs, focusing on the different mechanisms by which they control cardiac function in health and disease by regulating intracellular nanodomains.
Collapse
Affiliation(s)
- Kristen Kokkonen
- Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
| | - David A Kass
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; .,Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
| |
Collapse
|
14
|
Movsesian M. Novel approaches to targeting PDE3 in cardiovascular disease. Pharmacol Ther 2016; 163:74-81. [PMID: 27108947 DOI: 10.1016/j.pharmthera.2016.03.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2016] [Accepted: 03/18/2016] [Indexed: 10/24/2022]
Abstract
Inhibitors of PDE3, a family of dual-specificity cyclic nucleotide phosphodiesterases, are used clinically to increase cardiac contractility by raising intracellular cAMP content in cardiac myocytes and to reduce vascular resistance by increasing intracellular cGMP content in vascular smooth muscle myocytes. When used in the treatment of patients with heart failure, PDE3 inhibitors are effective in the acute setting but increase sudden cardiac death with long-term administration, possibly reflecting pro-apoptotic and pro-hypertrophic consequences of increased cAMP-mediated signaling in cardiac myocytes. cAMP-mediated signaling in cardiac myocytes is highly compartmentalized, and different phosphodiesterases, by controlling cAMP content in functionally discrete intracellular microcompartments, regulate different cAMP-mediated pathways. Four variants/isoforms of PDE3 (PDE3A1, PDE3A2, PDE3A3, and PDE3B) are expressed in cardiac myocytes, and new experimental results have demonstrated that these isoforms, which are differentially localized intracellularly through unique protein-protein interactions, control different physiologic responses. While the catalytic regions of these isoforms may be too similar to allow the catalytic activity of each isoform to be selectively inhibited, targeting their unique protein-protein interactions may allow desired responses to be elicited without the adverse consequences that limit the usefulness of existing PDE3 inhibitors.
Collapse
Affiliation(s)
- Matthew Movsesian
- VA Salt Lake City Health Care System, Salt Lake City, UT, USA; University of Utah, Salt Lake City, UT, USA.
| |
Collapse
|
15
|
New pharmacologic interventions to increase cardiac contractility: challenges and opportunities. Curr Opin Cardiol 2015; 30:285-91. [PMID: 25807221 DOI: 10.1097/hco.0000000000000165] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE OF REVIEW The most extensively studied inotropic agents in patients with heart failure are phosphodiesterase (PDE) 3 inhibitors, which increase contractility by raising intracellular cyclic adenosine monophosphate content. In clinical trials, the inotropic benefits of these agents have been outweighed by an increase in sudden cardiac death. Here, I review recent findings that help explain what are likely to be distinct mechanisms involved in the beneficial and adverse effects of PDE3 inhibition. RECENT FINDINGS The proapoptotic consequences of PDE3 inhibition are becoming more apparent. Moreover, it has also become clear that individual PDE3 isoforms in cardiac myocytes are selectively regulated to interact with different proteins in different intracellular compartments. The beneficial and adverse effects of PDE3 inhibition may thus be attributable to the inhibition of different isoforms in different intracellular domains. In particular, PDE3A1 has been shown to interact directly with sarcoplasmic/endoplasmic reticulum Ca ATPase (SERCA2) in the sarcoplasmic reticulum through a phosphorylation of a site in its unique N-terminal domain, making it possible that this isoform can be selectively targeted to increase intracellular Ca cycling. SUMMARY Conventional PDE3 inhibitors target several functionally distinct isoforms of these enzymes. Isoform-selective and/or compartment-selective targeting of PDE3, through its protein-protein interactions, may produce the inotropic benefits of PDE3 inhibition without the adverse consequences.
Collapse
|
16
|
Toka O, Tank J, Schächterle C, Aydin A, Maass PG, Elitok S, Bartels-Klein E, Hollfinger I, Lindschau C, Mai K, Boschmann M, Rahn G, Movsesian MA, Müller T, Doescher A, Gnoth S, Mühl A, Toka HR, Wefeld-Neuenfeld Y, Utz W, Töpper A, Jordan J, Schulz-Menger J, Klussmann E, Bähring S, Luft FC. Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactyly. Hypertension 2015; 66:800-8. [PMID: 26283042 DOI: 10.1161/hypertensionaha.115.06000] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2015] [Accepted: 07/24/2015] [Indexed: 12/30/2022]
Abstract
Autosomal-dominant hypertension with brachydactyly is a salt-independent Mendelian syndrome caused by activating mutations in the gene encoding phosphodiesterase 3A. These mutations increase the protein kinase A-mediated phosphorylation of phosphodiesterase 3A resulting in enhanced cAMP-hydrolytic affinity and accelerated cell proliferation. The phosphorylated vasodilator-stimulated phosphoprotein is diminished, and parathyroid hormone-related peptide is dysregulated, potentially accounting for all phenotypic features. Untreated patients die prematurely of stroke; however, hypertension-induced target-organ damage is otherwise hardly apparent. We conducted clinical studies of vascular function, cardiac functional imaging, platelet function in affected and nonaffected persons, and cell-based assays. Large-vessel and cardiac functions indeed seem to be preserved. The platelet studies showed normal platelet function. Cell-based studies demonstrated that available phosphodiesterase 3A inhibitors suppress the mutant isoforms. However, increasing cGMP to indirectly inhibit the enzyme seemed to have particular use. Our results shed more light on phosphodiesterase 3A activation and could be relevant to the treatment of severe hypertension in the general population.
Collapse
Affiliation(s)
- Okan Toka
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Jens Tank
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Carolin Schächterle
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Atakan Aydin
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Philipp G Maass
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Saban Elitok
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Eireen Bartels-Klein
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Irene Hollfinger
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Carsten Lindschau
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Knut Mai
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Michael Boschmann
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Gabriele Rahn
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Matthew A Movsesian
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Thomas Müller
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Andrea Doescher
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Simone Gnoth
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Astrid Mühl
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Hakan R Toka
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Yvette Wefeld-Neuenfeld
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Wolfgang Utz
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Agnieszka Töpper
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Jens Jordan
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Jeanette Schulz-Menger
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Enno Klussmann
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Sylvia Bähring
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.)
| | - Friedrich C Luft
- From the Children's' Hospital, Department of Pediatric Cardiology, Friedrich-Alexander University Erlangen, Erlangen, Germany (O.T.); Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany (J.T., J.J.); Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (C.S., A.A., P.G.M., E.B.-K., I.H., A.M., Y.W.-N., J.S.-M., E.K., S.B., F.C.L.); Experimental and Clinical Research Center (ECRC), a joint co-operation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (A.A., P.G.M., E.B.-K., I.H., C.L., K.M., M.B., G.R., A.M., Y.W.-N., W.U., A.T., J.S.-M., S.B., F.C.L.); Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (P.G.M.); Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA (P.G.M.); Department of Cardiology/Nephrology, Helios-Klinikum Berlin, Berlin, Germany (S.E., W.U., A.T., J.S.-M.); Department of Nephrology, Hannover University Medical School, Hannover, Germany (C.L.); Staatliche Technikerschule Berlin, Berlin, Germany (C.L.); Cardiology Section, VA Salt Lake City Health Care System, UT (M.A.M.); Departments of Internal Medicine and Pharmacology and Toxicology, University of Utah, Salt Lake City (M.A.M.); Blood Transfusion Center, Deutsches Rotes Kreuz, Oldenburg, Germany (T.M., A.D., S.G.); Division of Nephrology and Hypertension, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA (H.R.T.); Hampton Veterans Affairs Medical Center, Hampton, VA (H.R.T); German Centre for Cardiovascular Research (DZHK), Berlin, Germany (E.K.); and Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (F.C.L.).
| |
Collapse
|
17
|
|
18
|
Maass PG, Aydin A, Luft FC, Schächterle C, Weise A, Stricker S, Lindschau C, Vaegler M, Qadri F, Toka HR, Schulz H, Krawitz PM, Parkhomchuk D, Hecht J, Hollfinger I, Wefeld-Neuenfeld Y, Bartels-Klein E, Mühl A, Kann M, Schuster H, Chitayat D, Bialer MG, Wienker TF, Ott J, Rittscher K, Liehr T, Jordan J, Plessis G, Tank J, Mai K, Naraghi R, Hodge R, Hopp M, Hattenbach LO, Busjahn A, Rauch A, Vandeput F, Gong M, Rüschendorf F, Hübner N, Haller H, Mundlos S, Bilginturan N, Movsesian MA, Klussmann E, Toka O, Bähring S. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet 2015; 47:647-53. [PMID: 25961942 DOI: 10.1038/ng.3302] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Accepted: 04/17/2015] [Indexed: 01/02/2023]
Abstract
Cardiovascular disease is the most common cause of death worldwide, and hypertension is the major risk factor. Mendelian hypertension elucidates mechanisms of blood pressure regulation. Here we report six missense mutations in PDE3A (encoding phosphodiesterase 3A) in six unrelated families with mendelian hypertension and brachydactyly type E (HTNB). The syndrome features brachydactyly type E (BDE), severe salt-independent but age-dependent hypertension, an increased fibroblast growth rate, neurovascular contact at the rostral-ventrolateral medulla, altered baroreflex blood pressure regulation and death from stroke before age 50 years when untreated. In vitro analyses of mesenchymal stem cell-derived vascular smooth muscle cells (VSMCs) and chondrocytes provided insights into molecular pathogenesis. The mutations increased protein kinase A-mediated PDE3A phosphorylation and resulted in gain of function, with increased cAMP-hydrolytic activity and enhanced cell proliferation. Levels of phosphorylated VASP were diminished, and PTHrP levels were dysregulated. We suggest that the identified PDE3A mutations cause the syndrome. VSMC-expressed PDE3A deserves scrutiny as a therapeutic target for the treatment of hypertension.
Collapse
Affiliation(s)
- Philipp G Maass
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Atakan Aydin
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Friedrich C Luft
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [3] Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Carolin Schächterle
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Anja Weise
- Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena, Germany
| | - Sigmar Stricker
- 1] Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany
| | - Carsten Lindschau
- 1] Department of Nephrology, Hannover University Medical School, Hannover, Germany. [2] Staatliche Technikerschule Berlin, Berlin, Germany
| | - Martin Vaegler
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Department of Urology, Laboratory of Tissue Engineering, Eberhard Karls University Tübingen, Tübingen, Germany
| | - Fatimunnisa Qadri
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Hakan R Toka
- 1] Division of Nephrology and Hypertension, Eastern Virginia Medical School, Norfolk, Virginia, USA. [2] Division of Nephrology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Herbert Schulz
- 1] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany
| | - Peter M Krawitz
- 1] Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Institute for Medical Genetics and Human Genetics, Charité Universitätsmedizin Berlin, Berlin, Germany. [3] Berlin Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Dmitri Parkhomchuk
- 1] Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Institute for Medical Genetics and Human Genetics, Charité Universitätsmedizin Berlin, Berlin, Germany. [3] Berlin Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Jochen Hecht
- 1] Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Berlin Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Irene Hollfinger
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Yvette Wefeld-Neuenfeld
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Eireen Bartels-Klein
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Astrid Mühl
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Martin Kann
- 1] Department II of Medicine, University of Cologne, Cologne, Germany. [2] Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
| | | | - David Chitayat
- 1] Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. [2] Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | - Martin G Bialer
- 1] Division of Medical Genetics, North Shore/LIJ Health System, Manhasset, New York, USA. [2] Department of Pediatrics, North Shore/LIJ Health System, Manhasset, New York, USA
| | - Thomas F Wienker
- 1] Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany
| | - Jürg Ott
- 1] Institute of Psychology, Chinese Academy of Sciences, Beijing, China. [2] Statistical Genetics, Rockefeller University, New York, New York, USA
| | - Katharina Rittscher
- Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena, Germany
| | - Thomas Liehr
- Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena, Germany
| | - Jens Jordan
- Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
| | - Ghislaine Plessis
- Centre Hospitalier Universitaire de Caen, Cytogénétique Postnatale et Génétique Clinique, Caen, France
| | - Jens Tank
- Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
| | - Knut Mai
- Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Ramin Naraghi
- Department of Neurosurgery, Bundeswehrkrankenhaus Ulm, Ulm, Germany
| | - Russell Hodge
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Maxwell Hopp
- Department of Pediatrics, Griffith Base Hospital, Griffith, New South Wales, Australia
| | - Lars O Hattenbach
- Department of Ophthalmology, Hospital Ludwigshafen, Ludwigshafen, Germany
| | | | - Anita Rauch
- Institute for Medical Genetics, University of Zurich, Zurich, Switzerland
| | - Fabrice Vandeput
- 1] Cardiology Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA. [2] Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA. [3] Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA
| | - Maolian Gong
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Franz Rüschendorf
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Norbert Hübner
- 1] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] DZHK (German Centre for Cardiovascular Research), Berlin, Germany. [3] Charité Universitätsmedizin, Berlin, Germany
| | - Hermann Haller
- Department of Nephrology, Hannover University Medical School, Hannover, Germany
| | - Stefan Mundlos
- 1] Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Institute for Medical Genetics and Human Genetics, Charité Universitätsmedizin Berlin, Berlin, Germany. [3] Berlin Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Nihat Bilginturan
- Department of Pediatric Oncology, Hacettepe University, Ankara, Turkey
| | - Matthew A Movsesian
- 1] Cardiology Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA. [2] Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA. [3] Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA
| | - Enno Klussmann
- 1] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] DZHK (German Centre for Cardiovascular Research), Berlin, Germany
| | - Okan Toka
- Department of Pediatric Cardiology, Children's Hospital, Friedrich Alexander University Erlangen, Erlangen, Germany
| | - Sylvia Bähring
- 1] Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [2] Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| |
Collapse
|
19
|
Ahmad F, Shen W, Vandeput F, Szabo-Fresnais N, Krall J, Degerman E, Goetz F, Klussmann E, Movsesian M, Manganiello V. Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. J Biol Chem 2015; 290:6763-76. [PMID: 25593322 DOI: 10.1074/jbc.m115.638585] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Cyclic nucleotide phosphodiesterase 3A (PDE3) regulates cAMP-mediated signaling in the heart, and PDE3 inhibitors augment contractility in patients with heart failure. Studies in mice showed that PDE3A, not PDE3B, is the subfamily responsible for these inotropic effects and that murine PDE3A1 associates with sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2), phospholamban (PLB), and AKAP18 in a multiprotein signalosome in human sarcoplasmic reticulum (SR). Immunohistochemical staining demonstrated that PDE3A co-localizes in Z-bands of human cardiac myocytes with desmin, SERCA2, PLB, and AKAP18. In human SR fractions, cAMP increased PLB phosphorylation and SERCA2 activity; this was potentiated by PDE3 inhibition but not by PDE4 inhibition. During gel filtration chromatography of solubilized SR membranes, PDE3 activity was recovered in distinct high molecular weight (HMW) and low molecular weight (LMW) peaks. HMW peaks contained PDE3A1 and PDE3A2, whereas LMW peaks contained PDE3A1, PDE3A2, and PDE3A3. Western blotting showed that endogenous HMW PDE3A1 was the principal PKA-phosphorylated isoform. Phosphorylation of endogenous PDE3A by rPKAc increased cAMP-hydrolytic activity, correlated with shift of PDE3A from LMW to HMW peaks, and increased co-immunoprecipitation of SERCA2, cav3, PKA regulatory subunit (PKARII), PP2A, and AKAP18 with PDE3A. In experiments with recombinant proteins, phosphorylation of recombinant human PDE3A isoforms by recombinant PKA catalytic subunit increased co-immunoprecipitation with rSERCA2 and rat rAKAP18 (recombinant AKAP18). Deletion of the recombinant human PDE3A1/PDE3A2 N terminus blocked interactions with recombinant SERCA2. Serine-to-alanine substitutions identified Ser-292/Ser-293, a site unique to human PDE3A1, as the principal site regulating its interaction with SERCA2. These results indicate that phosphorylation of human PDE3A1 at a PKA site in its unique N-terminal extension promotes its incorporation into SERCA2/AKAP18 signalosomes, where it regulates a discrete cAMP pool that controls contractility by modulating phosphorylation-dependent protein-protein interactions, PLB phosphorylation, and SERCA2 activity.
Collapse
Affiliation(s)
- Faiyaz Ahmad
- From the Cardiovascular Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892,
| | - Weixing Shen
- From the Cardiovascular Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892
| | - Fabrice Vandeput
- VA Salt Lake City Health Care System and University of Utah, Salt Lake City, Utah
| | | | - Judith Krall
- VA Salt Lake City Health Care System and University of Utah, Salt Lake City, Utah
| | - Eva Degerman
- Department of Experimental Medical Science, Division for Diabetes, Metabolism, and Endocrinology, Lund University, Lund, Sweden
| | - Frank Goetz
- Max Delbrueck Center for Molecular Medicine Berlin-Buch (MDC), 13125 Germany, and
| | - Enno Klussmann
- Max Delbrueck Center for Molecular Medicine Berlin-Buch (MDC), 13125 Germany, and DZHK, German Centre for Cardiovascular Research, 13347 Berlin, Germany
| | - Matthew Movsesian
- VA Salt Lake City Health Care System and University of Utah, Salt Lake City, Utah
| | - Vincent Manganiello
- From the Cardiovascular Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892
| |
Collapse
|
20
|
Weninger S, Van Craenenbroeck K, Cameron RT, Vandeput F, Movsesian MA, Baillie GS, Lefebvre RA. Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling. Cell Signal 2014; 26:2573-82. [PMID: 25101859 DOI: 10.1016/j.cellsig.2014.07.027] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 06/28/2014] [Accepted: 07/28/2014] [Indexed: 12/14/2022]
Abstract
Phosphodiesterase (PDE) 3 and PDE4, which degrade cyclic adenosine monophosphate (cAMP), are important regulators of 5-hydroxytryptamine (5-HT) 4 receptor signaling in cardiac tissue. Therefore, we investigated whether they interact with the 5-HT4(b) receptor, and whether A-kinase anchoring proteins (AKAPs), scaffolding proteins that bind to the regulatory subunit of protein kinase A (PKA) and contribute to the spacial-temporal control of cAMP signaling, are involved in the regulation of 5-HT4(b) receptor signaling. By measuring PKA activity in the absence and presence of PDE3 and PDE4 inhibitiors, we found that constitutive signaling of the overexpressed HA-tagged 5-HT4(b) receptor in HEK293 cells is regulated predominantly by PDE4, with a secondary role for PDE3 that is unmasked in the presence of PDE4 inhibition. Overexpressed PDE4D3 and PDE3A1, and to a smaller extent PDE4D5 co-immunoprecipitate constitutively with the 5-HT4(b) receptor. PDE activity measurements in immunoprecipitates of the 5-HT4(b) receptor confirm the association of PDE4D3 with the receptor and provide evidence that the activity of this PDE may be increased upon receptor stimulation with 5-HT. A possible involvement of AKAPs in 5-HT4(b) receptor signaling was uncovered in experiments using the St-Ht31 inhibitor peptide, which disrupts the interaction of AKAPs with PKA. However, St-Ht31 did not influence 5-HT4(b) receptor-stimulated PKA activity, and endogenous AKAP79 and gravin were not found in immunoprecipitates of the 5-HT4(b) receptor. In conclusion, we found that both PDE3A1 and PDE4D3 are integrated into complexes that contain the 5-HT4(b) receptor and may thereby regulate 5-HT4(b) receptor-mediated signaling.
Collapse
Affiliation(s)
- S Weninger
- Heymans Institute of Pharmacology, Ghent University, De Pintelaan 185, Ghent 9000, Belgium
| | - K Van Craenenbroeck
- Laboratory for Eukaryotic Gene Expression and Signal Transduction, Ghent University, Proeftuinstraat 86, Ghent 9000, Belgium
| | - R T Cameron
- Institute of Cardiovascular and Medical Science, University of Glasgow, Office 534, Wolfson-Link Building, Glasgow G12 8QQ, UK
| | - F Vandeput
- Cardiovascular Medicine Division, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT 84148, USA
| | - M A Movsesian
- Cardiovascular Medicine Division, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT 84148, USA
| | - G S Baillie
- Institute of Cardiovascular and Medical Science, University of Glasgow, Office 534, Wolfson-Link Building, Glasgow G12 8QQ, UK
| | - R A Lefebvre
- Heymans Institute of Pharmacology, Ghent University, De Pintelaan 185, Ghent 9000, Belgium.
| |
Collapse
|
21
|
Cyclic AMP synthesis and hydrolysis in the normal and failing heart. Pflugers Arch 2014; 466:1163-75. [PMID: 24756197 DOI: 10.1007/s00424-014-1515-1] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Accepted: 04/03/2014] [Indexed: 12/12/2022]
Abstract
Cyclic AMP regulates a multitude of cellular responses and orchestrates a network of intracellular events. In the heart, cAMP is the main second messenger of the β-adrenergic receptor (β-AR) pathway producing positive chronotropic, inotropic, and lusitropic effects during sympathetic stimulation. Whereas short-term stimulation of β-AR/cAMP is beneficial for the heart, chronic activation of this pathway triggers pathological cardiac remodeling, which may ultimately lead to heart failure (HF). Cyclic AMP is controlled by two families of enzymes with opposite actions: adenylyl cyclases, which control cAMP production and phosphodiesterases, which control its degradation. The large number of families and isoforms of these enzymes, their different localization within the cell, and their organization in macromolecular complexes leads to a high level of compartmentation, both in space and time, of cAMP signaling in cardiac myocytes. Here, we review the expression level, molecular characteristics, functional properties, and roles of the different adenylyl cyclase and phosphodiesterase families expressed in heart muscle and the changes that occur in cardiac hypertrophy and failure.
Collapse
|